SPHK2 and neoplasm: Based on the above indicators treated with capecitabine and nivolumab, the presence of microbial SphK2 activity and the relative abundance of intratumoral ETBF were negatively correlated with tumor mutational burden (TMB) and carcinoembryonic antigen (CEA) levels (Figure S6D).